Palvellatx
NASDAQ: PVLAWayne, US · Founded 2015 · 55 employees on LinkedIn · 4 known investors
Find your way into Palvellatx
Palvella Therapeutics develops QTORIN™, a targeted topical formulation of rapamycin designed to treat rare skin diseases including microcystic lymphatic malformations and cutaneous venous malformations by delivering the active ingredient to the dermal layers with minimal systemic absorption.
Founders & leadership
Palvellatx was founded in 2015 by Wesley H. Kaupinen.
WH
Wesley H. KaupinenPresident, Chief Executive Officer and Director
ME
KG
Kathleen GoininChief Operating Officer
JM
Jeffrey MartiniinChief Scientific Officer
AK
Ashley KlineinChief Commercial Officer (CCO)Ashley Kline serves as Chief Commercial Officer at Palvella Therapeutics, which develops QTORIN™, a targeted topical rapamycin formulation for rare skin diseases. She has over a decade of experience in commercial leadership and strategic planning.
Investors · 4
Frequently asked questions
- What does Palvellatx do?
- Palvella Therapeutics develops QTORIN™, a targeted topical formulation of rapamycin designed to treat rare skin diseases including microcystic lymphatic malformations and cutaneous venous malformations by delivering the active ingredient to the dermal layers with minimal systemic absorption.
- Who founded Palvellatx?
- Palvellatx was founded by Wesley H. Kaupinen in 2015.
- Who are Palvellatx's investors?
- Palvellatx's investors include BioAdvance, Frazier Life Sciences, Samsara BioCapital, Agent Capital.
- Where is Palvellatx headquartered?
- Palvellatx is headquartered in Wayne, US.